Editas And Celgene Amend Existing Collaboration To Develop And Commercialize Autologous And Allogeneic T Cell Medicines For Treatment Of Cancer And Autoimmune Diseases; Editas To Receive $70M And Is Eligible For Royalty And Milestone Payments

Benzinga · 11/12/2019 12:21